CoChat

Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors

Open access
Baldelli, Elisa, Bellezza, Guido, Haura, Eric B., Crinó, Lucio, Cress, W. Douglas, Deng, Jianghong, Ludovini, Vienna, Sidoni, Angelo, Schabath, Matthew B., Puma, Francesco, Vannucci, Jacopo, Siggillino, Annamaria, Liotta, Lance A., Petricoin, Emanuel F., Pierobon, Mariaelena · 2015 · Oncotarget
Cited by 35

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

// Elisa Baldelli 1,2 , Guido Bellezza 3 , Eric B. Haura 4 , Lucio Crinó 2 , W. Douglas Cress 4 , Jianghong Deng 1 , Vienna Ludovini 2 , Angelo Sidoni 3 , Matthew B. Schabath 4 , Francesco Puma 5 , Jacopo Vannucci 5 , Annamaria Siggillino 2 , Lance A. Liotta 1 , Emanuel F. Petricoin III 1 and Mariaelena Pierobon 1 1 Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA, USA 2 Medical Oncology Division, S. Maria della Misericordia Hospital, Perugia, Italy 3 Department of Experimental Medicine, Section of Anatomic Pathology and Histology, Medical School, University of Perugia, Perugia, Italy 4 Department of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA 5 Department of Thoracic Surgery, University of Perugia, Perugia, Italy Correspondence to: Mariaelena Pierobon, email: // Keywords : signaling networks, KRAS mutation, laser capture microdissection, reverse phase protein microarray, non-small cell lung cancers Received : August 24, 2015 Accepted : August 30, 2015 Published : September 30, 2015 Abstract Little is known about the complex signaling architecture of KRAS and the interconnected RAS-driven protein-protein interactions, especially as it occurs in human clinical specimens. This study explored the activated and interconnected signaling network of KRAS mutant lung adenocarcinomas (AD) to identify novel therapeutic targets. Thirty-four KRAS mutant (MT) and twenty-four KRAS wild-type (WT) frozen biospecimens were obtained from surgically treated lung ADs. Samples were subjected to laser capture microdissection and reverse phase protein microarray analysis to explore the expression/activation levels of 150 signaling proteins along with co-activation concordance mapping. An independent set of 90 non-small cell lung cancers (NSCLC) was used to validate selected findings by immunohistochemistry (IHC). Compared to KRAS WT tumors, the signaling architecture of KRAS MT ADs revealed significant interactions between KRAS downstream substrates, the AKT/mTOR pathway, and a number of Receptor Tyrosine Kinases (RTK). Approximately one-third of the KRAS MT tumors had ERK activation greater than the WT counterpart (p<0.01). Notably 18% of the KRAS MT tumors had elevated activation of the Estrogen Receptor alpha (ER-α) ( p =0.02).This finding was verified in an independent population by IHC ( p =0.03). KRAS MT lung ADs appear to have a more intricate RAS linked signaling network than WT tumors with linkage to many RTKs and to the AKT-mTOR pathway. Combination therapy targeting different nodes of this network may be necessary to treat this group of patients. In addition, for patients with KRAS MT tumors and activation of the ER-α, anti-estrogen therapy may have important clinical implications.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.5941

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

Metadata

Authors
Baldelli, E., Bellezza, G., Haura, E. B., Crinó, L., Cress, W. D., Deng, J., Ludovini, V., Sidoni, A., Schabath, M. B., Puma, F., Vannucci, J., Siggillino, A., Liotta, L. A., Petricoin, E. F., & Pierobon, M.
Venue
Oncotarget
Published
2015-09-30
Volume
6
Issue
32
Pages
32368-32379
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2195289941
Cited by
35
References
9
FWCI
1.90
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.